New Stockholm3 data accepted for presentation at the upcoming European Association of Urology meeting
February 10, 2023
Seven scientific abstracts, one thematic session and one plenary session related to Stockholm3 have been accepted for presentation at the upcoming 38th European Association of Urology (EAU) meeting that will be held March-10-13 in Milan, Italy.
The accepted presentations, outlined below, cover topics such as validation of Stockholm3 in new populations, experience from use of Stockholm3 in clinical practice and early mortality data from the original population based-Stockholm3 screening.
“The interest for Stockholm3 continues to grow in Europe and it is very encouraging to see external validation of the algorithm in countries outside Scandinavia, 5-year results after incorporating Stockholm3 into a clinical care system in the Stockholm community and six-year interim data evaluating prostate cancer mortality after one-time screening using Stockholm3. This further supports evidence for use of Stockholm3 as a reliable decision tool in selection of men for prostate cancer testing,” says Hari Vigneswaran MD, Director of Medical Affairs at A3P Biomedical.
The full abstracts are available today on the EAU23 virtual platform (here).
About A3P Biomedical
A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com
About Stockholm3
Stockholm3 is a blood-based test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.
Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml. Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 40-90% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 40-50% compared to PSA.
Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about our clinical studies please visit www.a3p.com.
About prostate cancer
Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.
Press contact:
Cecilia Edström
cecilia.edstrom@a3p.com
+46 72 226 2328